MagneVal™ (magnesium valproate hydrate)
- US Patent through 2026
- Valproate current standard of care for epilepsy
- MagneVal™formulations in water offer dosing advantages
- Advantages for therapeutics & safety
- Outstanding bioavailability
- Significantly less gastric irritation than sodium valproate or divalproex sodium
LiVal™ (lithium valproate)
- Provided as a stable salt with high water solubility
CarneVal-C™ and CarneVal-M™ (provide both valproate & L-carnitine)
- Water-soluble salts for easy oral formulation
- Therapeutics & Safety
- L-Carnitine reported to enhance cell function & mitigate toxicity in children
These patented valproates are NDA candidates
All of these valproates are available for licensing
|
|